When did VITEK 2 AST-Streptococcus Cefuroxime ( =8 µg/mL) receive FDA 510(k) clearance?

VITEK 2 AST-Streptococcus Cefuroxime ( =8 µg/mL) received FDA 510(k) clearance on 2026-03-26, under 510(k) number K260281.

FDA 510(k)

VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)

K-Number: K260281 · 2026-03-26

ApplicantBIOMERIEUX

Decision Date2026-03-26

Product CodeLON

Advisory CommitteeMI

DecisionSubstantially Equivalent

Device Summary

VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) is the device name listed in this FDA 510(k) record. The listed applicant is BIOMERIEUX. It received FDA 510(k) clearance on 2026-03-26 under 510(k) number K260281. The device is classified under product code LON. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)?

VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) is a medical device that received FDA 510(k) clearance on 2026-03-26. The listed applicant is BIOMERIEUX. The 510(k) number is K260281.

When did VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) receive FDA 510(k) clearance?

VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) received FDA 510(k) clearance on 2026-03-26, under 510(k) number K260281.

Who is the listed applicant for VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)?

The FDA 510(k) record lists BIOMERIEUX as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)?

The FDA product code for VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL) is LON.

Other records listing BIOMERIEUX as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST System K260282VITEK 2 AST-Streptococcus Inducible Clindamycin Resistance K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)K234012VITEK COMPACT PRO K232967VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)

View all 69 devices →

Related Devices (Code: LON)

K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc.K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc.K251713BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)Becton, Dickinson and Company K250447BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)Becton, Dickinson and Company K234012VITEK COMPACT PRObioMerieux, Inc.K250344BD Phoenix™ Automated Microbiology SystemBecton, Dickinson and Company

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.